In this episode, we explore KarXT, a groundbreaking experimental antipsychotic that works through the cholinergic system rather than dopamine pathways. Could this novel approach revolutionize schizophrenia treatment by offering similar efficacy to current antipsychotics but without the motor side effects?

Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.

• Learn more about our membership here
• Earn 0.75 CMEs: Quick Take Vol. 63
• Xanomeline-Trospium (KarXT) Shows Efficacy in Phase 3 Trial for Schizophrenia